glp 1 and gip receptors Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes The dual GIP/GLP-1 mechanisms. GIP

Meneilly participated on a GSM Advisory Board for Merck and Novo Nordisk, and received speaking fees from Boehringer Ingelheim, Lilly, and Merck

Even so, we dont have strong clinical research that follows breastfeeding parents and babies over time

For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred

GLP-1 Support GLP-1 drugs are an emerging class of compounds intended to help treat type 2 diabetes and obesity

Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates

Demand for such drugs is likely to continue to be strong in the future due to rising rates of obesity and interlinked chronic diseases